

**International Nonproprietary Names (INN)  
for biological and biotechnological substances**

**(a review)**

**2016**



**World Health  
Organization**



# **International Nonproprietary Names (INN) for biological and biotechnological substances**

**(a review)**

**2016**



**World Health  
Organization**

International Nonproprietary Names (INN) Programme

**Technologies Standards and Norms (TSN)  
Regulation of Medicines and other Health Technologies (RHT)  
Essential Medicines and Health Products (EMP)**

# **International Nonproprietary Names (INN) for biological and biotechnological substances**

**(a review)**

FORMER DOCUMENT NUMBER: INN Working Document 05.179
---

**© World Health Organization 2016**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

**Printed by the WHO Document Production Services, Geneva, Switzerland**

# TABLE OF CONTENTS

INTRODUCTION .....	1
1. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES [1-7].....	3
1.1. Groups with respective stems.....	3
1.2. Groups with INN schemes .....	4
1.3. Groups without respective stems / pre-stems.....	4
2. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES.....	5
2.1. General policies for non-glycosylated compounds [8].....	5
2.2. General policies for glycosylated compounds [8].....	5
2.3. General policies for fusion proteins [4] .....	6
2.4. General policies for pegylated substances [22].....	6
2.5. General policies for cell therapy products (CTP).....	6
2.6. General policies for gene therapy products (GTP)[2] .....	8
2.7. General policies for monoclonal antibodies [1, 3, 11, 23] .....	9
2.8. General policies for blood products [4] .....	11
2.9. General policies for immunoglobulins fractionated from plasma [9, 10].....	11
2.10. General policies for skin substitutes [4] .....	11
2.11. General policies for transgenic substances [4] ( <i>under discussion</i> ) .....	11
2.12. General policies for vaccines [4-7] ( <i>under discussion</i> ) .....	12
3. SUMMARY OF INN ASSIGNED TO BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES [1, 3, 7, 8, 13-21].....	13
3.1. Antimicrobial, bactericidal permeability increasing polypeptides.....	13
3.2. Antisense oligonucleotides.....	13
3.3. Antithrombins.....	13
3.4. Aptamers, classical and mirror ones.....	13
3.5. Blood coagulation cascade inhibitors .....	14
3.6. Blood coagulation factors .....	14
3.7. Cell therapy products (CTP) .....	15
3.8. Colony stimulating factors (CSF).....	15
3.9. Enzymes .....	16
3.10. Erythropoietin type blood factors.....	19
3.11. Gene therapy products .....	19
3.12. Gonadotropin-releasing hormone (GnRH) inhibiting peptides.....	20
3.13. Growth factors and Tumour Necrosis Factors (TNF).....	20
3.14. Growth hormone (GH) derivatives.....	21
3.15. Growth hormone (GH) antagonists .....	21
3.16. Heparin derivatives including low molecular mass heparins.....	21
3.17. Hirudin derivatives .....	21
3.18. Immunomodulators, both stimulant/suppressive and stimulant ( <i>under discussion</i> ).....	22
3.19. Insulins .....	22
3.20. Interferons .....	23
3.21. Interleukin receptor antagonists .....	23
3.22. Interleukin type substances .....	24
3.23. Monoclonal antibodies.....	25
3.24. Oxytocin derivatives.....	30

3.25.	Peptides and Glycopeptides .....	30
3.26.	Pituitary / Placental glycoprotein hormones .....	33
3.27.	Pituitary hormone-release stimulating peptides .....	33
3.28.	Receptor molecules, native or modified ( <i>under discussion</i> ) .....	34
3.29.	Small interfering RNA .....	35
3.30.	Synthetic polypeptides with a corticotropin-like action .....	35
3.31.	Thrombomodulins .....	35
3.32.	Toxins .....	35
3.33.	Vasoconstrictors, vasopressin derivatives .....	35
3.34.	Vaccine-like substances (eg. peptide vaccines, recombinant vaccines) .....	36
3.35.	Various .....	37
	CURRENT CHALLENGES .....	41
	REFERENCES .....	43
	ANNEX 1 .....	45
	The list of INN for fusion proteins .....	45
	ANNEX 2 .....	55
	List of INN for conjugated proteins .....	55
	ANNEX 3 .....	65
	List of INN for pegylated substances .....	65
	ANNEX 4 .....	67
	Transliteration of Greek letters in English, French and Spanish .....	67
	ANNEX 5 .....	69
	The previous naming scheme for monoclonal antibodies .....	69

## INTRODUCTION

More than 50 years ago, WHO established the International Nonproprietary Name (INN) Expert Group/WHO Expert Committee on Specifications for Pharmaceutical Preparations, to assign nonproprietary names to medicinal substances, so that each substance would be recognized globally by a unique name. These INNs do not give proprietary rights, unlike a trade mark, and can be used freely as they are public property.

INNs have been assigned to biological products since the early days of the INN Programme. As well as many names for individual substances, animal insulin preparations were given an INN in Recommended list 3 in 1959. In the period up to 1980, names were assigned to antibiotics, synthetic peptides, hormones and other proteins. In names of compounds related by structure and/or function, specific letter groups, called stems, are included to aid recognition by health professionals. The *-actide* for synthetic polypeptides with a corticotrophin-like action is an early example.

In 1982, the name *insulin human* was proposed for the recombinant protein identical to natural human insulin, and since then names have been assigned to a growing number of recombinant products. Within the INN Programme, names have not been assigned to natural human blood products or vaccines. For those groups of biological products, the WHO Expert Committee on Biological Standardization (ECBS) has been adopting the scientific names of the biological products within the definitions of respective requirements.

Since the time when *insulin human* became the first recommended INN (rINN) for a recombinant product, the range of biological/biotechnological products has increased in size and complexity. For example, new stems have been introduced for tissue plasminogen activators (*-plase*) among other groups. Recombinant glycosylated proteins with the same protein sequence but produced in different cell systems have been classified using Greek letters as indicators in the sequence of submission for an INN, for example erythropoietin gives *epoetin alfa*, *epoetin beta* and so on. In the 1990s, a systematic scheme for naming monoclonal antibodies was implemented, based on the stem *-mab*, which indicates the origin (human, mouse etc) of the antibody and its intended use: for example tumour, immunomodulator and so on.

As a result of the scientific and technical developments over the past few years and continuing now, new products of biotechnology and other biological products have been developed and approved for clinical use and more products can be expected for the treatment or prevention of disease. Examples include recombinant blood products, transgenic products (human proteins expressed in animals or plants), products for gene and cell therapy and novel vaccines.

As this area became more and more complex and challenging, the INN Expert Group requested the WHO-INN Secretariat to prepare a working document intended to summarize and review the past and present INN situation activities and policies in this field.

This document, first published on the website of the INN Programme in 2006, presents an inventory of the policy decisions taken by the INN Expert Group during all these years of

change, and of the names assigned to biological and biotechnological substances. Considering the potential for further developments in the field of biologicals, this review is intended to be a *living document* which is updated regularly to include new policies, and INNs that have been assigned. The current version has been revised fully to reflect discussions and decisions taken by the INN Expert Group following a comprehensive review undertaken by many experts in the field, the INN Expert Group and Secretariat.

Comments and suggestions from all interested parties are always welcome and will be presented to the INN Expert Group for their consideration and for possible incorporation in future updates of this review.

You are reading the current updated version, also available as pdf-copy at:

<http://www.who.int/medicines/services/inn/publication/en/index.html>.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27209](https://www.yunbaogao.cn/report/index/report?reportId=5_27209)

